glp-1 review article receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read GLP-1 Receptor Agonists | New
Description
Gabery, S
But as their use expands, clinicians are increasingly recognizing that medications alone are not enough
Why This Matters for Patients For many people, weight management is not simply about willpower
When transitioning from semaglutide to another diabetes medication, clinicians should anticipate overlapping drug effects for several weeks
Diabetes Care 43 , 28592869 (2020)
